Off-label prescribing is a common practice in dermatology, particularly when uncommon dermatologic diseases have limited or no approved treatment options. Topical calcineurin inhibitors are approved for the treatment of eczema, and their anti-inflammatory, immunomodulatory, and steroid-sparing effects make them an attractive therapeutic option for a wide variety of other dermatologic diseases. This review summarizes and qualifies the available evidence supporting the clinical effectiveness of tacrolimus ointment and pimecrolimus cream in non-eczema indications. There is high-quality evidence supporting the effectiveness of topical calcineurin inhibitors in multiple dermatological disorders including vitiligo; psoriasis of the face, folds, and genitals; seborrheic dermatitis; chronic hand dermatitis; contact dermatitis; oral lichen planus; lichen sclerosus; morphea; and cutaneous lupus erythematosus. Lower-quality evidence suggests they may be considered as an option in many other cutaneous disorders.
WooDKJamesWD.Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005;16(1):6-21. doi:10.1097/01206501-200503000-00003
2.
WollinaUHanselGKochAAbdel-NaserMB.Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin Pharmacother. 2006;7(14):1967-1975. doi:10.1517/14656566.7.14.1967
3.
HenggeUR, ed. Tacrolimus Ointment in Special Treatment Indications. Stuttgart, Germany: Thieme Verlag KG; 2018:1-84.
Elidel® (pimecrolimus) product monograph. Bausch Health Canada. https://pdf.hres.ca/dpd_pm/00030576.PDF. Published September 4, 2014. Accessed October 16, 2018.
6.
WongEKurianA.Off-label uses of topical calcineurin inhibitors. Skin Ther Lett. 2016;21(1):8-10.
7.
LargentEAMillerFGPearsonSD.Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169(19):1745-1747. doi:10.1001/archinternmed.2009.314
8.
SugarmanJHFleischer ABJrFeldmanSR.Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217-223. doi:10.1067/mjd.2002.120469
9.
RadleyDCFinkelsteinSNStaffordRS.Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-1026. doi:10.1001/archinte.166.9.1021
EichenfieldLFTomWLBergerTG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023
13.
WollenbergABarbarotSBieberT, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657-682. doi:10.1111/jdv.14888
14.
FiorilloLMarcouxDRamienM. Contemporary role of topical calcineurin inhibitors: A pediatric dermatology perspective. J Cutan Med Surg. 2019 (in press).
15.
HoNPopeEWeinsteinMGreenbergSWebsterCKrafchikBR. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. Br J Dermatol. 2011;165(3):626-632. doi:10.1111/j.1365-2133.2011.10351.x
16.
LubakiLJGhanemGVereeckenP, et al. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus. Arch Dermatol Res. 2010;302(2):131-137. doi:10.1007/s00403-009-0973-3
17.
BaldoALodiGDi CaterinoPMonfrecolaG.Vitiligo, NB-UVB and tacrolimus: our experience in Naples. G Ital Dermatol Venereol. 2014;149(1):123-130.
18.
RadakovicSBreier-MalyJKonschitzkyR, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol. 2009;23(8):951-953. doi:10.1111/j.1468-3083.2009.03138.x
19.
DawidMVeensaluMGrassbergerMWolffK.Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006;4(11):942-946. doi:10.1111/j.1610-0387.2006.06124.x
20.
LepeVMoncadaBCastanedo-CazaresJPTorres-AlvarezMBOrtizCATorres-RubalcavaAB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139(5):581-585. doi:10.1001/archderm.139.5.581
21.
SistiASistiGOrangesCM.Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. An Bras Dermatol. 2016;91(2):187-195. doi:10.1590/abd1806-4841.20164012
22.
CavaliéMEzzedineKFontasE, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970-974. doi:10.1038/jid.2014.527
23.
LiRQiaoMWangXZhaoXSunQ.Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta-analysis. Photodermatol Photoimmunol Photomed. 2017;33(1):22-31. doi:10.1111/phpp.12277
24.
DangYPLiQShiFYuanXYLiuW.Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016;29(2):126-133. doi:10.1111/dth.12295
25.
BaeJMHongBYLeeJHLeeJHKimGM.The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016;74(5):907-915. doi:10.1016/j.jaad.2015.11.044
26.
de MenezesAFOliveiradeCarvalhoFBarretoRS, et al. Pharmacologic treatment of vitiligo in children and adolescents: a systematic review. Pediatr Dermatol. 2017;34(1):13-24. doi:10.1111/pde.13024
27.
GawkrodgerDJOrmerodADShawL, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159(5):1051-1076. doi:10.1111/j.1365-2133.2008.08881.x
28.
GuptaAKVersteegSG.Topical treatment of facial seborrheic dermatitis: a systematic review. Am J Clin Dermatol. 2017;18(2):193-213. doi:10.1007/s40257-016-0232-2
29.
Ang-TiuCUMeghrajaniCFMaanoCC.Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012;5(1):91-97. doi:10.1586/ecp.11.68
30.
KastarinenHOksanenTOkokonEO, et al. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446. doi:10.1002/14651858.CD009446.pub2
31.
HaldMArendrupMCSvejgaardEL, et al. Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases. Acta Derm Venereol. 2015;95(1):12-19. doi:10.2340/00015555-1825.
32.
PappKAPappADahmerBClarkCS.Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults. J Am Acad Dermatol. 2012;67(1):e11-e15. doi:10.1016/j.jaad.2011.02.032
33.
WarshawEMWohlhuterRJLiuA, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57(2):257-264. doi:10.1016/j.jaad.2006.11.007
34.
FiroozASolhpourAGorouhiF, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142(8):1066-1067. doi:10.1001/archderm.142.8.1066
35.
HordinskyMFleischerARiversJKPoulinYBelsitoDHultschT.Efficacy and safety of pimecrolimus cream 1% in mild-to-moderate chronic hand dermatitis: a randomized, double-blind trial. Dermatology. 2010;221(1):71-77. doi:10.1159/000297524
36.
BelsitoDVFowler JFJrMarks JGJr, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73(1):31-38.
37.
Krejci-ManwaringJMcCartyMACamachoF, et al. Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol. 2008;7(7):643-646.
38.
SchnoppCRemlingRMöhrenschlagerMWeiglLRingJAbeckD.Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol. 2002;46(1):73-77. doi:10.1067/mjd.2002.117856
39.
SaripalliYVGadziaJEBelsitoDV.Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol. 2003;49(3):477-482. doi:10.1067/S0190-9622(03)01826-7
40.
PacorMLDi LorenzoGMartinelliN, et al. Tacrolimus ointment in nickel sulphate-induced steroid-resistant allergic contact dermatitis. Allergy Asthma Proc. 2006;27(6):527-531. doi:10.2500/aap.2006.27.2915
41.
BelsitoDWilsonDCWarshawE, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol. 2006;55(1):40-46. doi:10.1016/j.jaad.2006.03.025
42.
KatsarouAMakrisMPapagiannakiKLagogianniETagkaAKalogeromitrosD.Tacrolimus 0.1% vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol. 2012;22(2):192-196. doi:10.1684/ejd.2011.1615
43.
AlomarAPuigLGallardoCMValenzuelaN.Topical tacrolimus 0.1% ointment (Protopic®) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis. 2003;49(4):185-188. doi:10.1111/j.0105-1873.2003.0217.x
44.
AmrolDKeitelDHagamanDMurrayJ.Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol. 2003;91(6):563-566. doi:10.1016/S1081-1206(10)61535-9
45.
JungerstedJMHøghJKHellegrenLIJemecGBAgnerT.Effects of topical corticosteroid and tacrolimus on ceramides and irritancy to sodium lauryl sulphate in healthy skin. Acta Derm Venereol. 2011;91(3):290-294. doi:10.2340/00015555-1064
46.
EngelKReuterJSeilerCSchulte MöntingJJakobTSchemppCM.Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test. J Eur Acad Dermatol Venereol. 2008;22(4):447-450. doi:10.1111/j.1468-3083.2007.02477.x
47.
SchwarzTKreiselmaierIBieberT, et al. A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. J Am Acad Dermatol. 2008;59(1):34-40. doi:10.1016/j.jaad.2008.03.043
48.
OppelTPavicicTKamannSBräutigamMWollenbergA.Pimecrolimus cream (1%) efficacy in perioral dermatitis – results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol. 2007;21(9):1175-1180. doi:10.1111/j.1468-3083.2007.02191.x
49.
KravvasGGholamK.Use of topical therapies for pediatric psoriasis: a systematic review. Pediatr Dermatol. 2018;35(3):296-302. doi:10.1111/pde.13422
50.
de JagerMEde JongEMvan de KerkhofPCSeygerMM.Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013-1030. doi:10.1016/j.jaad.2009.06.048
51.
LebwohlMFreemanAKChapmanMS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5):723-730. doi:10.1016/j.jaad.2004.07.011
52.
LiaoYHChiuHCTsengYSTsaiTF.Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol. 2007;157(5):1005-1012. doi:10.1111/j.1365-2133.2007.08201.x
53.
KreuterASommerAHyunJ, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142(9):1138-1143. doi:10.1001/archderm.142.9.1138
54.
GribetzCLingMLebwohlM, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-738. doi:10.1016/j.jaad.2004.06.010
55.
AlbrechtLBourcierMAshkenasJ, et al. Topical psoriasis therapy in the age of biologics: evidence-based treatment recommendations. J Cutan Med Surg. 2011;15(6):309-321. doi:10.2310/7750.2011.10080
56.
MenterAKormanNJElmetsCA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032
57.
KalbREBagelJKormanNJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(1):120-124. doi:10.1016/j.jaad.2008.06.041
ChiCCKirtschigGBaldoMLewisFWangSHWojnarowskaF.Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus. J Am Acad Dermatol. 2012;67(2):305-312. doi:10.1016/j.jaad.2012.02.044
60.
GoldsteinATCreaseyAPfauRPhillipsDBurrowsLJ.A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2011;64(6):e99-e104. doi:10.1016/j.jaad.2010.06.011
61.
FunaroDLovettALerouxNPowellJ.A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol. 2014;71(1):84-91. doi:10.1016/j.jaad.2014.02.019
62.
Bercaw-PrattJLBoardmanLASimms-CendanJS; North American Society for Pediatric and Adolescent Gynecology. Clinical recommendation: pediatric lichen sclerosus. J Pediatr Adolesc Gynecol. 2014;27(2):111-116. doi:10.1016/j.jpag.2013.11.004
63.
Pérez-LópezFRCeausuIDepypereH, et al. EMAS clinical guide: vulvar lichen sclerosus in peri and postmenopausal women. Maturitas. 2013;74(3):279-282. doi:10.1016/j.maturitas.2012.12.006
64.
ZwischenbergerBAJacobeHT.A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65(5):925-941. doi:10.1016/j.jaad.2010.09.006
65.
KroftEBGroeneveldTDSeygerMMde JongEM.Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181-187. doi:10.2165/00128071-200910030-00004
66.
MancusoGBerdondiniRM.Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol. 2005;152(1):180-182. doi:10.1111/j.1365-2133.2004.06318.x
67.
StefanakiCStefanakiKKontochristopoulosG, et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study. J Dermatol. 2008;35(11):712-718. doi:10.1111/j.1346-8138.2008.00552.x
68.
TzellosTGKouvelasD.Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol. 2008;64(4):337-341. doi:10.1007/s00228-007-0421-2
69.
ZonneveldIMRubinsAJablonskaS, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134(9):1101-1102. doi:10.1001/archderm.134.9.1101
70.
RivardJJanigaJLimHW.Tacrolimus ointment 0.1% alone and in combination with medium-dose UVA1 in the treatment of palmar or plantar psoriasis. J Drugs Dermatol. 2006;5(6):505-510.
71.
HendriksAGKeijsersRRde JongEMSeygerMMvan de KerkhofPC.Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(8):931-951. doi:10.1111/jdv.12058
72.
GhislainPDDe DeckerILachapelleJM.Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. Br J Dermatol. 2004;150(5):1052-1053. doi:10.1111/j.1365-2133.2004.05914.x
73.
AliFRLyonCC.Tacrolimus toxicity following topical treatment of perianal Crohn’s disease: an admonitory anecdote. J Crohns Colitis. 2013;7(12):e713. doi:10.1016/j.crohns.2013.08.013
74.
Lonsdale-EcclesAAVelangiS.Herpes simplex of the vulva evoked by topical tacrolimus treatment. Clin Exp Dermatol. 2005;30(1):95-96. doi:10.1111/j.1365-2230.2004.01673.x
75.
Feito-RodríguezMNoguera-MorelLCasas-RiveroJGarcía-RodríguezJde Lucas-LagunaR.Bacterial vaginosis in the context of lichen sclerosus in a prepubertal girl. Pediatr Dermatol. 2014;31(1):95-98. doi:10.1111/pde.12227
76.
BilenchiRPoggialiSDe PadovaLAPisaniCDe PaolaMFimianiM.Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. Br J Dermatol. 2007;156(2):405-406. doi: 10.1111/j.1365-2133.2006.07662.x
77.
HannaSZipCShearNH. What is the risk of harm associated with topical calcineurin inhibitors?J Cutan Med Surg. 2019 (in press).
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
